Stanford Medicine scientists explain what we know, and what we don’t know, about living with COVID-19 two years after the World Health Organization declared a pandemic.

Stanford Medicine’s clinical virology laboratory has processed its 1 millionth COVID-19 test nearly two years after becoming one of the first academic center testing sites in the country.

COVID-19 vaccines are better than infection at making antibodies to recognize new viral variants, according to a Stanford study.

Rituximab, a drug widely used in patients with lymphoma, blunts or eliminates the antibody response to COVID-19 vaccines if it is administered before them, Stanford researchers say.

A look at antibodies in patients soon after they were infected with the virus that causes COVID-19 showed key differences between those whose cases remained mild and those who later developed severe symptoms.

The Doris Duke foundation has awarded the Stanford School of Medicine $550,000 to aid physician-scientists with family caregiving responsibilities heightened by COVID-19.

After a dramatic drop in nonessential surgery rates early in the pandemic, U.S. hospitals quickly adapted to new safety protocols, and rates returned to normal, Stanford Medicine research shows.

The Moderna and Pfizer BioNTech vaccines prevented COVID-19 infection in cancer patients, particularly in those whose treatment concluded more than six months before vaccination, say researchers at Stanford, Harvard and the VA.

In the final installment of The Pandemic Puzzle: Lessons from COVID-19, leaders in government, academia, health care and business said biomedical and digital health advances of the last few years will help combat future health crises.

Data suggest that between 10% and 30% of those who have had an acute SARS-CoV-2 infection will experience the persistent pattern of symptoms known as long COVID.